The rise in number of reimbursed delegates in 2002 will come from an increased number of ad hoc meetings related to the evaluation of medicinal products for human use, increased use of experts in the designation process for orphan medicines and also from preparation and implementation of a number of special projects, in particular relating to the Agency’ s future role in the Community pharmaceuticals regulatory IT strategy.